Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Next Previous
Search
Drug Profile

Cobicistat/darunavir/emtricitabine/tenofovir alafenamide - Janssen R&D Ireland

Alternative Names: Cobicistat/darunavir/emtricitabine/GS 7340; Cobicistat/darunavir/emtricitabine/GS 7340 fixed-dose combination - Janssen; Darunavir/cobicistat/emtricitabine/GS-7340; Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide; Darunavir/emtricitabine/GS 7340/cobicistat; Emtricitabine/GS 7340/cobicistat/darunavir; GS 7340/cobicistat/darunavir/emtricitabine; SYMTUZA; Tenofovir alafenamide/cobicistat/darunavir/emtricitabine

Latest Information Update: 04 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides
  • Mechanism of Action Cytochrome P-450 enzyme system inhibitors; DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase II inhibitors; DNA-directed DNA polymerase inhibitors; HIV protease inhibitors; HIV reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 17 Jun 2024 Gilead Sciences in collaboration with Janssen Pharmaceuticals completes the LAPTOP phase III trial for HIV-1 infections in Belgium, France, Germany, Ireland, Italy, the UK and Spain (NCT03696160)
  • 28 Feb 2023 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in Netherlands (PO, Tablet)
  • 28 Nov 2022 No recent reports of development identified for phase-I development in HIV-1-infections(In children) in Spain (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top